Studies a kidney test in adults with diabetes and chronic kidney disease
Looks at how a kidney test affects care for adults with diabetic kidney disease.
Key facts
- Who runs it
- Renalytix AI, Inc.
- Where
- New York, United StatesSee the site
- Trial code
- Registry title
- Real World Evidence Clinical Utility Study of KidneyIntelX
- Status
- Recruiting
- People taking part
- 10,000 people, planned
- Started
- 2 Mar 2021
- Expected to end
- 1 Dec 2026
- Type of study
- Observational
- Treatments tested
- KidneyIntelX
- Record updated
- 13 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes and chronic kidney disease who are seen in the primary care office at Mount Sinai. It studies how the KidneyIntelX test affects their care.
- Age
- 23 years and older
- Sex
- All sexes can join.
- Disease stage
- Type 2 diabetes with chronic (diabetic) kidney disease, stages G3a-G3b or G1-G2 with A2-A3, by KDIGO CKD staging.
- Earlier treatment
- Must have at least 6 months of medical history before the KidneyIntelX baseline. Cannot be on renal recovery treatments or currently on Enbrel.
Main reasons for not taking part
- eGFR below 30, or 60 and above without albuminuria
- End-stage kidney disease (ESRD) or on renal recovery treatments
- Pregnant at the time of enrollment
- Currently in hospital
- Currently taking Enbrel
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Individuals with Type 2 diabetes and concurrent chronic (diabetic) kidney disease (G3a-G3b or G1-G2, A2-A3) per KDIGO CKD staging
Who cannot take part
- Patients who are currently on Enbrel
- Patients with eGFR <30 or ≥ 60 ml/min/1.73m2 without albuminuria
- Patents without the appropriate characteristics as identified in the KidneyIntelX intended use population
- Patients with ESRD or on renal recovery treatments at time of enrollment
- Patients who are pregnant at the time of enrollment
- Patients who are currently hospitalized
- Patients without minimum 6 month pre-baseline KidneyIntelX medical history
Where in United States
- Mount Sinai Health SystemNew York, United StatesContact: Roger TunTaking people
About the trial
What the trial wants to find out
The purpose of this study is to assess the impact of the KidneyIntelX assay utilized as part of the current standard of care on the management of patients seen in the primary care physician's office at Mount Sinai.
Treatments tested
- KidneyIntelX
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Real World Evidence Clinical Utility Study of KidneyIntelX in Patients With Type 2 Diabetes and Chronic Kidney Disease
- Plain-language title
- Studies a kidney test in adults with diabetes and chronic kidney diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 13 August 2026